Clinical Trial Update: Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Aumolertinib, with or without chemotherapy, as first-line treatment for locally advanced or metastatic non-small cell lung cancer with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Aumolertinib (Aumolertinib)

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING